Lupus Nephritis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Lupus Nephritis – Drugs In Development, 2024 report and make more profitable business decisions.
Lupus nephritis is a severe complication of systemic lupus erythematosus (SLE), an autoimmune disease that affects various organs, tissues, and systems within the body. Lupus nephritis specifically involves inflammation of the kidneys, leading to kidney damage and impaired kidney function.
In systSLE, the body’s immune system mistakenly attacks its own tissues and organs, including the kidneys, causing inflammation. Not all individuals with SLE develop lupus nephritis, but it can significantly impact those who do.
Symptoms of lupus nephritis can vary widely, ranging from mild to severe, and can include high blood pressure; swelling, particularly in the legs, feet, hands, or face; dark urine or blood in the urine; proteinuria (excessive protein in the urine); reduced urine output; fatigue; and general discomfort.
The Lupus Nephritis drugs in development market research report provide comprehensive information on the therapeutics under development for Lupus Nephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lupus Nephritis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Lupus Nephritis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 70 molecules, with 68 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Lupus Nephritis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Lupus Nephritis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Lupus Nephritis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
149 Bio LLCAbbVie Inc
Alexion Pharmaceuticals Inc
Alphamab Oncology
Alpine Immune Sciences Inc
Amgen Inc
Annexon Inc
Apellis Pharmaceuticals Inc
Aria Pharmaceuticals Inc
Asahi Kasei Pharma Corp
AstraZeneca Plc
Astria Therapeutics Inc
BeiGene Ltd
Beijing Mabworks Biotech Co Ltd
Bellvitge Biomedical Research Institute
BioAegis Therapeutics Inc
Biocon Ltd
Bristol-Myers Squibb Co
Cabaletta Bio Inc
Capricor Therapeutics Inc
Cellenkos Inc
Chinook Therapeutics Inc
Chugai Pharmaceutical Co Ltd
Corestemchemon Inc
Createrna Science and Technology Co Ltd
Eledon Pharmaceuticals Inc
Equillium Inc
Everest Medicines Ltd
F. Hoffmann-La Roche Ltd
Genrix (Shanghai) Biopharmaceutical Co Ltd
Horizon Therapeutics Plc
ImmPACT Bio USA Inc
ImmuneID Inc
Inflection Biosciences Ltd
Innovent Biologics Inc
Jiangsu Hengrui Medicine Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
Jiangsu Ruiyuan Biotechnology Co Ltd
Johnson & Johnson
Juventas Cell Therapy Ltd
Kezar Life Sciences Inc
Kyverna Therapeutics Inc
Lepton Pharmaceuticals Ltd
MorphoSys AG
Mysthera Therapeutics AG
Neutrolis Inc
Nkarta Inc
Novartis AG
NovelMed Therapeutics Inc
Omeros Corp
Orbsen Therapeutics Ltd
Pfizer Inc
Ra Pharmaceuticals Inc
RemeGen Co Ltd
Resolve Therapeutics LLC
Sana Biotechnology Inc
SciRhom GmbH
Serenity Bioworks Inc
Slate Bio Inc
Transcenta Holding Ltd
UCB SA
University of Southern California
Zai Lab Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Lupus Nephritis reports